Vor Biopharma’s (VOR) “Outperform” Rating Reaffirmed at Wedbush

Wedbush reiterated their outperform rating on shares of Vor Biopharma (NYSE:VOR) in a research note published on Thursday, MarketBeat.com reports.

VOR has been the topic of a number of other reports. Stifel Nicolaus lowered their price target on Vor Biopharma from $12.00 to $5.00 and set a “buy” rating on the stock in a research report on Friday, March 21st. Baird R W lowered Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Citizens Jmp lowered Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 9th. Jones Trading lowered Vor Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Vor Biopharma in a research report on Friday, May 9th. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.06.

Vor Biopharma Price Performance

Shares of NYSE:VOR opened at $0.89 on Thursday. The business’s fifty day moving average price is $0.35 and its two-hundred day moving average price is $0.83. Vor Biopharma has a fifty-two week low of $0.13 and a fifty-two week high of $1.80. The stock has a market capitalization of $111.21 million, a price-to-earnings ratio of -0.54 and a beta of -0.51.

Institutional Trading of Vor Biopharma

Several institutional investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. boosted its stake in Vor Biopharma by 74.3% in the 4th quarter. RA Capital Management L.P. now owns 39,646,039 shares of the company’s stock valued at $44,007,000 after purchasing an additional 16,897,159 shares during the period. Lynx1 Capital Management LP bought a new stake in Vor Biopharma in the 4th quarter valued at $707,000. Jane Street Group LLC bought a new stake in Vor Biopharma in the 1st quarter valued at $140,000. Two Sigma Investments LP boosted its stake in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company’s stock valued at $181,000 after purchasing an additional 25,930 shares during the period. Finally, Northern Trust Corp boosted its stake in Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company’s stock valued at $175,000 after purchasing an additional 44,252 shares during the period. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.